Clinical Updates in Treating Advanced Prostate Cancer - Episode 2

Treatment Timelines Related to Disease State and Use of Monotherapy

,

Panelists discuss the current treatment landscape for metastatic castration-sensitive prostate cancer (mHSPC), exploring main therapeutic approaches, the role of androgen deprivation monotherapy, the timing for adding chemotherapy and ARPIs, and strategies for sequencing or combining these modalities in clinical practice.

EP. 1: Treatment Landscape and Sequencing of Therapies
Now Viewing
EP. 2: Treatment Timelines Related to Disease State and Use of Monotherapy
EP. 3: Genetic Testing – Germline
EP. 4: Recent Data on ARPI-Based Combination Regimens
EP. 5: Genetic Testing – Somatic
EP. 6: ARPI-Based Combination Regimens – PEACE-3 (Radium-223 and enzalutamide)
EP. 7: Use of Bone Protection Agents
EP. 8: ARPI-Based Combination Regimens – ARANOTE (Darolutamide and ADT)
EP. 9: ARPI-Based Combination Regimens – CONTACT-02 (Cabozantinib plus atezolizumab)
EP. 10: ARPI-Based Combination Regimens – SPLASH (177 Lu-PNT-2002)
EP. 11: Key Takeaways and Looking Ahead

  • What is the current treatment landscape for metastatic castration-sensitive prostate cancer (mHSPC)? What are the main therapeutic approaches typically utilized for these patients?
  • Is there still a role for androgen deprivation monotherapy in any setting? Why or why not?
  • When do you consider the addition of chemotherapy and ARPIs?
  • How do you approach sequencing or combining these different modalities in your practice?

Related Content:

Clinical Updates in Treating Advanced Prostate Cancer
ARPI-Based Combination Regimens – CONTACT-02 (Cabozantinib plus atezolizumab)
ARPI-Based Combination Regimens – SPLASH (177 Lu-PNT-2002)
Key Takeaways and Looking Ahead